Alector reports initial data from INFRONT trial subset at AAIC
Alector reported initial data from a subset of patients in the company's INFRONT clinical study of its product candidate, AL001. AL001 is being evaluated for the treatment of patients with frontotemporal dementia with a granulin mutation, or FTD-GRN. The data were presented at the Alzheimer's Association International Conference, or AAIC. The data presented are from 50 healthy volunteers and four patients with FTD-GRN Based on these initial findings in the INFRONT clinical study, AL001 was seen to be generally safe and well-tolerated up to the highest dose level. Data show that AL001 elicited a dose-dependent increase in PGRN levels in both plasma and cerebrospinal fluid, or CSF, of healthy volunteers and FTD-GRN patients. Specifically, AL001 tripled the level of PGRN in the plasma and doubled the level of PGRN in the CSF of both asymptomatic and symptomatic FTD-GRN patients, restoring the level of PGRN back to the normal range. A Phase 2 clinical trial in FTD-GRN patients is expected to start in the second half of 2019.